Paulson Wealth Management Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,712 shares of the company’s stock after buying an additional 115 shares during the quarter. Paulson Wealth Management Inc.’s holdings in Johnson & Johnson were worth $702,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Lake Point Wealth Management boosted its holdings in shares of Johnson & Johnson by 144.4% during the first quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock worth $38,000 after purchasing an additional 169 shares during the last quarter. Islay Capital Management LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $42,000. FAI Wealth Management boosted its holdings in shares of Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its holdings in shares of Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the last quarter. Finally, HWG Holdings LP acquired a new stake in shares of Johnson & Johnson during the second quarter worth $49,000. Hedge funds and other institutional investors own 67.44% of the company’s stock.
Shares of NYSE JNJ opened at $148.10 on Friday. Johnson & Johnson has a 1 year low of $109.16 and a 1 year high of $157.00. The firm has a market cap of $389.92 billion, a price-to-earnings ratio of 23.29, a PEG ratio of 3.36 and a beta of 0.68. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. The stock’s 50-day simple moving average is $148.57 and its 200-day simple moving average is $146.59.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The business had revenue of $21.08 billion for the quarter, compared to analyst estimates of $20.15 billion. During the same period in the previous year, the company earned $2.12 earnings per share. The company’s revenue for the quarter was up 1.7% compared to the same quarter last year. As a group, research analysts predict that Johnson & Johnson will post 8 EPS for the current year.
In related news, EVP Ashley Mcevoy sold 29,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $147.47, for a total value of $4,276,630.00. Following the completion of the transaction, the executive vice president now directly owns 21,682 shares in the company, valued at $3,197,444.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares of the company’s stock, valued at $10,233,336.16. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by company insiders.
Several research firms have recently issued reports on JNJ. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Raymond James increased their target price on Johnson & Johnson from $157.00 to $158.00 and gave the stock an “outperform” rating in a research report on Friday, July 17th. Zacks Investment Research lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price on the stock. in a research report on Tuesday, July 7th. Cantor Fitzgerald increased their target price on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Independent Research raised Johnson & Johnson from a “hold” rating to a “buy” rating and increased their target price for the stock from $161.00 to $164.00 in a research report on Monday, July 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $164.93.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: How to invest using market indexes
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.